Bringing lung cancer out of the shadow
Facts on the United Kingdom Lung Cancer Coalition
What is the UKLCC?
The UK Lung Cancer Coalition (UKLCC) is a powerful new coalition of the UK’s leading lung cancer experts, senior NHS and Department of Health professionals, charities and healthcare companies. Itis the UK’s largest multi-interest group in lung cancer and it is the first time that all the major charities with an interest in the disease have joined forces to fight lung cancer.
Lung cancer is the UK’s biggest cancer killer1; it kills over 33,000 people each year1. This is more than breast cancer, prostate cancer, bladder cancer and leukaemia combined.1 Half of all people diagnosed with lung cancer die within six months.2
Why has the UKLCC been established?
The UKLCC has been established to launch the nation’s largest-ever attack on lung cancer and bring lung cancer out of the political, clinical and media shadow.
All members believe that lung cancer research, diagnosis, treatment, public awareness and patient information are currently inadequate in the UK.
Despite improvements in services, there is a wide variation in survival rates across England. Currently, as a result of socioeconomics and health provision inequalities, you are four times more likely to survive from lung cancer in Chelsea, Stockport and Solihull than you are in Northumberland, Rotherham or Sunderland.3
The UKLCC believes that lung cancer gets a raw deal when compared to other cancers. Despite accounting for a quarter of all cancer deaths,4 lung cancer only receives three per cent of all current UK cancer research funding.5 This is a travesty.
Who are the UKLCC?
The UKLCC consists of a partnership of some of the country’s leading lung cancer experts, senior NHS and Department of Health professionals, charities and healthcare companies who are committed to, and have a shared interest in, improving the survival and quality of life of patients with lung cancer.
Currently, there are 24 members of the UKLCC. They are:-
NHS / Clinical / Professional:
- Dr Mick Peake, Chairman of Intercollegiate Lung Cancer Group; National Lead Clinician for Lung Cancer, Cancer Services Collaborative; Consultant Physician, University Hospitals of Leicester Trust
- Dr Stephen Falk, Consultant Clinical Oncologist, Bristol Haematology and Oncology Centre
- Dr Joe Maguire, Consultant Clinical Oncologist, Liverpool Lung Cancer Unit
- Professor Stephen Spiro, Head of the Dept of Respiratory Medicine, University College Hospital
- Mr Richard Steyn, Consultant Thoracic Surgeon, Birmingham Heartlands and Solihull NHS Trust
- Mr Roger Vaughan, Consultant Thoracic Surgeon, Birmingham Heartlands and Solihull NHS Trust
- Gilmour Frew, NHS Cancer Services Collaborative ‘Improvement Partnership’
- General Practice Airways Group (GPiAG)
- National Lung Cancer Forum for Nurses
- British Lung Foundation (Secretariat)
- Cancer Black Care
- Cancer Research UK
- Macmillan Cancer Relief
- Marie Curie Cancer Care
- Roy Castle Lung Cancer Foundation
- AstraZeneca UK Ltd
- Lilly UK
- Pierre Fabre
- Roche Products Ltd
- Unisoft Medical Systems
What are the key aims and objectives of the UKLCC?
The UKLCC’s key objectives are to:-
- Raise political awareness of lung cancer
- Raise the general public’s awareness of lung cancer – and especially encourage earlier presentation and symptom recognition
- Empower patients to take an active part in their care
- Improve lung cancer services in the UK
- Increase research funding for lung cancer
By doing so, and by universally adopting the best standards which already exist in the NHS, we believe we can double survival.
What is the UKLCC’s long-term vision?
TheUKLCC is committed to doubling one year lung cancer patient survival by 2010 and five year survival by 2015. Currently, only around a quarter of people with lung cancer in England and Wales (24%) 6 will live for a year and less than one in ten (6% in England and Wales) are still alive five years after diagnosis.7
How can people contact the UKLCC?
C/o British Lung Foundation
73-75 Goswell Road
Tel: 0207 688 5565
Note to editors:
The UKLCC’s launch activities are being funded by its own membership.
Currently the UKLCC receives benefit in kind from the British Lung Foundation (secretariat and treasury services) and Unisoft Medical Systems (website design) and grants from Unisoft, Pierre Fabre, AstraZeneca, Lilly UK, sanofi-aventis and Roche.
For further information, please contact:-
Lynsey Conway on 07778 304233
2 Cancer research UK Statistics Dept
4 Cancer Atlas of UK and Ireland, 2005. Chapter 13, p139
5 http://www.ncri.org.uk/publications/index.cfm?NavSub=20 NCRI Strategic Analysis 2002 pdf
6 One- and five-year survival of patients diagnosed in 1991-95 and 1996-99: major cancers, sex and age, England and Wales. 2005. (Accessed at http://www.statistics.gov.uk/StatBase/Product.asp?vlnk=10821.)
Coleman M, Rachet B, Woods L, et al.Trends in socioeconomic inequalities in cancer survival in England and Wales up to 2001. British Journal of Cancer 2004;